DIPG Panel Discussion, page-100

Every 6 weeks or so - new independent and separate research becomes available on google, detailing scientific reasons, why a PI3K mTOR inhibition may enhance radiation in cancer.

This is what this highly qualified and respected Dr Yang, (in charge of the paxalisib / radiation FDA study, was quoted on 7 July)......

----------------------
Paxalisib is therefore a logical choice of drug and, combined with radiotherapy, it may help overcome this resistance," Jonathan Yang, MD, PhD, director of metastatic disease and developmental therapeutics, Department of Radiation Oncology, University

__________________________

The second stage of the FDA study has been expanded, and in fact - beautifully hidden away on page 26 of that 26th June Kazia Corporate ASX presentation .........one brain metastases patient has had an 81% response rate to pax and radiation. That means despite 4 or 5 other previous attempted treatments with the best drugs drugs available - now the cancer tumor is almost completely gone. Page 26, top left.

It is completely beyond anyone's wildest imagination - as to the worth of this drug paxalisib, if as it is becoming more and more likely - paxalisib will work to better radiation treatment.

So I don't know - just a big disappointment this stock. .....but I would be genuinely frightened not to be holding, with at least a significant position. News over in the states could see it reopen on the ASX next day 300% higher- a sickening feeling to hold the stock so long, and then miss out on that.